210 related articles for article (PubMed ID: 24733895)
1. PDGFRβ reverses EphB4 signaling in alveolar rhabdomyosarcoma.
Aslam MI; Abraham J; Mansoor A; Druker BJ; Tyner JW; Keller C
Proc Natl Acad Sci U S A; 2014 Apr; 111(17):6383-8. PubMed ID: 24733895
[TBL] [Abstract][Full Text] [Related]
2. Role of Src tyrosine kinases in experimental pulmonary hypertension.
Pullamsetti SS; Berghausen EM; Dabral S; Tretyn A; Butrous E; Savai R; Butrous G; Dahal BK; Brandes RP; Ghofrani HA; Weissmann N; Grimminger F; Seeger W; Rosenkranz S; Schermuly RT
Arterioscler Thromb Vasc Biol; 2012 Jun; 32(6):1354-65. PubMed ID: 22516066
[TBL] [Abstract][Full Text] [Related]
3. EphB4/EphrinB2 therapeutics in Rhabdomyosarcoma.
Randolph ME; Cleary MM; Bajwa Z; Svalina MN; Young MC; Mansoor A; Kaur P; Bult CJ; Goros MW; Michalek JE; Xiang S; Keck J; Krasnoperov V; Gill P; Keller C
PLoS One; 2017; 12(8):e0183161. PubMed ID: 28817624
[TBL] [Abstract][Full Text] [Related]
4. Selective inhibition of PDGFR by imatinib elicits the sustained activation of ERK and downstream receptor signaling in malignant glioma cells.
Dong Y; Jia L; Wang X; Tan X; Xu J; Deng Z; Jiang T; Rainov NG; Li B; Ren H
Int J Oncol; 2011 Feb; 38(2):555-69. PubMed ID: 21152856
[TBL] [Abstract][Full Text] [Related]
5. Hypoxia- or PDGF-BB-dependent paxillin tyrosine phosphorylation in pulmonary hypertension is reversed by HIF-1α depletion or imatinib treatment.
Veith C; Zakrzewicz D; Dahal BK; Bálint Z; Murmann K; Wygrecka M; Seeger W; Schermuly RT; Weissmann N; Kwapiszewska G
Thromb Haemost; 2014 Dec; 112(6):1288-303. PubMed ID: 25231004
[TBL] [Abstract][Full Text] [Related]
6. The tyrosine kinase inhibitor dasatinib effectively blocks PDGF-induced orbital fibroblast activation.
Virakul S; Dalm VA; Paridaens D; van den Bosch WA; Hirankarn N; van Hagen PM; Dik WA
Graefes Arch Clin Exp Ophthalmol; 2014 Jul; 252(7):1101-9. PubMed ID: 24874745
[TBL] [Abstract][Full Text] [Related]
7. The small molecule specific EphB4 kinase inhibitor NVP-BHG712 inhibits VEGF driven angiogenesis.
Martiny-Baron G; Holzer P; Billy E; Schnell C; Brueggen J; Ferretti M; Schmiedeberg N; Wood JM; Furet P; Imbach P
Angiogenesis; 2010 Sep; 13(3):259-67. PubMed ID: 20803239
[TBL] [Abstract][Full Text] [Related]
8. Potentiation of platelet-derived growth factor receptor-β signaling mediated by integrin-associated MFG-E8.
Motegi S; Garfield S; Feng X; Sárdy M; Udey MC
Arterioscler Thromb Vasc Biol; 2011 Nov; 31(11):2653-64. PubMed ID: 21868707
[TBL] [Abstract][Full Text] [Related]
9. Imatinib disrupts lymphoma angiogenesis by targeting vascular pericytes.
Ruan J; Luo M; Wang C; Fan L; Yang SN; Cardenas M; Geng H; Leonard JP; Melnick A; Cerchietti L; Hajjar KA
Blood; 2013 Jun; 121(26):5192-202. PubMed ID: 23632889
[TBL] [Abstract][Full Text] [Related]
10. Evidence for a dual function of EphB4 as tumor promoter and suppressor regulated by the absence or presence of the ephrin-B2 ligand.
Rutkowski R; Mertens-Walker I; Lisle JE; Herington AC; Stephenson SA
Int J Cancer; 2012 Sep; 131(5):E614-24. PubMed ID: 22161689
[TBL] [Abstract][Full Text] [Related]
11. PDGF beta-receptor kinase activity and ERK1/2 mediate glycosaminoglycan elongation on biglycan and increases binding to LDL.
Getachew R; Ballinger ML; Burch ML; Reid JJ; Khachigian LM; Wight TN; Little PJ; Osman N
Endocrinology; 2010 Sep; 151(9):4356-67. PubMed ID: 20610572
[TBL] [Abstract][Full Text] [Related]
12. Low concentrations of TNF-α promote osteogenic differentiation via activation of the ephrinB2-EphB4 signalling pathway.
Wang L; Zhang J; Wang C; Qi Y; Du M; Liu W; Yang C; Yang P
Cell Prolif; 2017 Feb; 50(1):. PubMed ID: 27726217
[TBL] [Abstract][Full Text] [Related]
13. Expression of platelet-derived growth factor receptor β is maintained by Prox1 in lymphatic endothelial cells and is required for tumor lymphangiogenesis.
Miyazaki H; Yoshimatsu Y; Akatsu Y; Mishima K; Fukayama M; Watabe T; Miyazono K
Cancer Sci; 2014 Sep; 105(9):1116-23. PubMed ID: 24981766
[TBL] [Abstract][Full Text] [Related]
14. Imatinib mesylate inhibits the proliferation-stimulating effect of human lung cancer-associated stromal fibroblasts on lung cancer cells.
Kinoshita K; Nakagawa K; Hamada J; Hida Y; Tada M; Kondo S; Moriuchi T
Int J Oncol; 2010 Oct; 37(4):869-77. PubMed ID: 20811709
[TBL] [Abstract][Full Text] [Related]
15. Soluble EphB4 inhibition of PDGF-induced RPE migration in vitro.
He S; Kumar SR; Zhou P; Krasnoperov V; Ryan SJ; Gill PS; Hinton DR
Invest Ophthalmol Vis Sci; 2010 Jan; 51(1):543-52. PubMed ID: 19696168
[TBL] [Abstract][Full Text] [Related]
16. Ephrin B2/EphB4 pathway in hepatic stellate cells stimulates Erk-dependent VEGF production and sinusoidal endothelial cell recruitment.
Das A; Shergill U; Thakur L; Sinha S; Urrutia R; Mukhopadhyay D; Shah VH
Am J Physiol Gastrointest Liver Physiol; 2010 Jun; 298(6):G908-15. PubMed ID: 20338920
[TBL] [Abstract][Full Text] [Related]
17. PDGF-induced vascular smooth muscle cell proliferation is associated with dysregulation of insulin receptor substrates.
Zhao Y; Biswas SK; McNulty PH; Kozak M; Jun JY; Segar L
Am J Physiol Cell Physiol; 2011 Jun; 300(6):C1375-85. PubMed ID: 21325637
[TBL] [Abstract][Full Text] [Related]
18. Receptor tyrosine kinase EphB4 is a survival factor in breast cancer.
Kumar SR; Singh J; Xia G; Krasnoperov V; Hassanieh L; Ley EJ; Scehnet J; Kumar NG; Hawes D; Press MF; Weaver FA; Gill PS
Am J Pathol; 2006 Jul; 169(1):279-93. PubMed ID: 16816380
[TBL] [Abstract][Full Text] [Related]
19. Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma.
Kubo T; Piperdi S; Rosenblum J; Antonescu CR; Chen W; Kim HS; Huvos AG; Sowers R; Meyers PA; Healey JH; Gorlick R
Cancer; 2008 May; 112(10):2119-29. PubMed ID: 18338812
[TBL] [Abstract][Full Text] [Related]
20. BCR-ABL-independent and RAS / MAPK pathway-dependent form of imatinib resistance in Ph-positive acute lymphoblastic leukemia cell line with activation of EphB4.
Suzuki M; Abe A; Imagama S; Nomura Y; Tanizaki R; Minami Y; Hayakawa F; Ito Y; Katsumi A; Yamamoto K; Emi N; Kiyoi H; Naoe T
Eur J Haematol; 2010 Mar; 84(3):229-38. PubMed ID: 20002159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
